These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15857724)

  • 21. Co-morbid drug and alcohol and mental health issues in a rural New South Wales Area Health Service.
    Hoolahan B; Kelly B; Stain HJ; Killen D
    Aust J Rural Health; 2006 Aug; 14(4):148-53. PubMed ID: 16911163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community-based co-occurring disorder (COD) intermediate and advanced treatment for offenders.
    Melnick G; Coen C; Taxman FS; Sacks S; Zinsser KM
    Behav Sci Law; 2008; 26(4):457-73. PubMed ID: 18683204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addiction treatment services and co-occurring disorders: Prevalence estimates, treatment practices, and barriers.
    McGovern MP; Xie H; Segal SR; Siembab L; Drake RE
    J Subst Abuse Treat; 2006 Oct; 31(3):267-75. PubMed ID: 16996389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of a prerelease substance abuse treatment program for repeat criminal offenders.
    French MT; Fang H; Fretz R
    J Subst Abuse Treat; 2010 Jan; 38(1):31-41. PubMed ID: 19631489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addressing psychiatric comorbidity.
    Woody GE; McLellan AT; O'Brien CP; Luborsky L
    NIDA Res Monogr; 1991; 106():152-66. PubMed ID: 1922285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a training program to improve clinicians' assessment of patient stability.
    Winstock AR; Lea T
    Drug Alcohol Rev; 2009 Jul; 28(4):353-9. PubMed ID: 19594788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-occurring disorders in the adolescent mental health and substance abuse treatment systems.
    Turner WC; Muck RD; Muck RJ; Stephens RL; Sukumar B
    J Psychoactive Drugs; 2004 Dec; 36(4):455-62. PubMed ID: 15751483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bringing sex and gender into women's substance use treatment programs.
    Greaves L; Poole N
    Subst Use Misuse; 2008 Jul; 43(8-9):1271-3. PubMed ID: 18649246
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment for dual diagnosis patients in the psychiatric and substance abuse systems.
    Timko C; Dixon K; Moos RH
    Ment Health Serv Res; 2005 Dec; 7(4):229-42. PubMed ID: 16320106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing the world: the design and implementation of comprehensive continuous integrated systems of care for individuals with co-occurring disorders.
    Minkoff K; Cline CA
    Psychiatr Clin North Am; 2004 Dec; 27(4):727-43. PubMed ID: 15550290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adolescent substance use and abuse: recognition and management.
    Griswold KS; Aronoff H; Kernan JB; Kahn LS
    Am Fam Physician; 2008 Feb; 77(3):331-6. PubMed ID: 18297958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A national survey of care for persons with co-occurring mental and substance use disorders.
    Watkins KE; Burnam A; Kung FY; Paddock S
    Psychiatr Serv; 2001 Aug; 52(8):1062-8. PubMed ID: 11474052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substance abuse issues among women in domestic violence programs: findings from North Carolina.
    Martin SL; Moracco KE; Chang JC; Council CL; Dulli LS
    Violence Against Women; 2008 Sep; 14(9):985-97. PubMed ID: 18703771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of residential treatment retention among individuals with co-occurring substance abuse and mental health disorders.
    Choi S; Adams SM; MacMaster SA; Seiters J
    J Psychoactive Drugs; 2013; 45(2):122-31. PubMed ID: 23909000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Public sector managed care: a comparative evaluation of substance abuse treatment in three counties.
    Beattie M; McDaniel P; Bond J
    Addiction; 2006 Jun; 101(6):857-72. PubMed ID: 16696630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The substance abuse treatment system in the U.S. What is it? What does it do? Myths and misconceptions.
    Rawson RA; Obert JL
    Occup Med; 2002; 17(1):27-39, iii-iv. PubMed ID: 11726334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.
    Gelkopf M; Weizman T; Melamed Y; Adelson M; Bleich A
    Isr J Psychiatry Relat Sci; 2006; 43(2):126-36. PubMed ID: 16910375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and struggles: lived experiences of individuals with co-occurring disorders.
    Villena AL; Chesla CA
    Arch Psychiatr Nurs; 2010 Apr; 24(2):76-88. PubMed ID: 20303448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.